[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Lee JH, Gong H, Khadem S, Lu Y, Gao X, Li S, Zhang J, Xie W: Androgen deprivation by activating the liver X receptor. Endocrinology; 2008 Aug;149(8):3778-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The androgens-androgen receptor signaling plays an important role in normal prostate development, as well as in prostatic diseases, such as benign hyperplasia and prostate cancer.
  • Genetic or pharmacological activation of the liver X receptor (LXR) in vivo lowered androgenic activity by inducing the hydroxysteroid sulfotransferase 2A1, an enzyme essential for the metabolic deactivation of androgens.
  • Activation of LXR also inhibited the expression of steroid sulfatase in the prostate, which may have helped to prevent the local conversion of sulfonated androgens back to active metabolites.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Biotechnol. 1999 Dec;10(6):557-63 [10600692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):728-33 [8570624.001]
  • [Cites] Genes Dev. 2000 Nov 15;14(22):2819-30 [11090130.001]
  • [Cites] Genes Dev. 2000 Nov 15;14(22):2831-8 [11090131.001]
  • [Cites] Pathol Res Pract. 1996 Jul;192(7):752-60 [8880876.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):670-97 [8969973.001]
  • [Cites] Chem Biol Interact. 1998 Feb 20;109(1-3):267-78 [9566751.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21856-66 [9705324.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4092-101 [9751487.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7686-9 [15520170.001]
  • [Cites] Clin Sci (Lond). 2005 Jan;108(1):1-11 [15384949.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17813-8 [15601766.001]
  • [Cites] Mol Endocrinol. 2005 Jan;19(1):184-97 [15388788.001]
  • [Cites] Hepatology. 2005 Jan;41(1):168-76 [15619241.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):101-7 [15788642.001]
  • [Cites] Endocr Rev. 2005 Apr;26(2):171-202 [15561802.001]
  • [Cites] Biol Reprod. 2005 Nov;73(5):951-8 [16014817.001]
  • [Cites] J Lipid Res. 2005 Dec;46(12):2657-66 [16150827.001]
  • [Cites] Nat Rev Immunol. 2006 Jan;6(1):44-55 [16493426.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2815-25 [16510604.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):607-14 [16511593.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):358-65 [16778563.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):379-85 [16778565.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):778-87 [11159850.001]
  • [Cites] Mutat Res. 2001 Oct 1;482(1-2):27-40 [11535246.001]
  • [Cites] Steroids. 2001 Sep;66(9):673-81 [11546555.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6482-6 [16818617.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1902-12 [16823488.001]
  • [Cites] Urol Int. 2006;77(2):135-8 [16888418.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10513-6 [17079473.001]
  • [Cites] Drug Metab Dispos. 2007 Jan;35(1):121-7 [17050650.001]
  • [Cites] Prostate. 2007 Mar 1;67(4):405-9 [17187396.001]
  • [Cites] Hepatology. 2007 Feb;45(2):422-32 [17256725.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1843-9 [17194744.001]
  • [Cites] Mol Endocrinol. 2007 May;21(5):1014-27 [17341595.001]
  • [Cites] Diabetes. 2007 Jun;56(6):1534-43 [17369526.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1781-90 [17536009.001]
  • [Cites] J Med Chem. 2002 May 9;45(10):1963-6 [11985463.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):280-9 [11594786.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38378-87 [11504730.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7558-68 [11604492.001]
  • [Cites] Drug Metab Dispos. 2002 May;30(5):582-5 [11950791.001]
  • [Cites] Biochem J. 2002 May 15;364(Pt 1):165-71 [11988089.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):389-96 [12044015.001]
  • [Cites] Int J Urol. 2002 Jun;9(6):359-61 [12110102.001]
  • [Cites] Endocr Rev. 2002 Oct;23(5):703-32 [12372849.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1243-8 [12411951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2226-30 [12589022.001]
  • [Cites] Mol Endocrinol. 2003 Jun;17(6):985-93 [12690094.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36091-8 [12847102.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):44593-9 [12923182.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):89-101 [14619959.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):54-69 [14689582.001]
  • [Cites] Mol Pharmacol. 2004 Feb;65(2):292-300 [14742670.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):765-71 [14744796.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):276-308 [15082523.001]
  • [Cites] Trends Endocrinol Metab. 2004 May-Jun;15(4):158-65 [15109614.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Cell. 2004 Oct 15;119(2):299-309 [15479645.001]
  • [Cites] Prostate. 1987;11(3):229-42 [3684783.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:159-76 [10836131.001]
  • (PMID = 18450964.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES014626; United States / NIEHS NIH HHS / ES / ES014626
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Benzoates; 0 / Benzylamines; 0 / DNA-Binding Proteins; 0 / GW 3965; 0 / Hydroxycholesterols; 0 / Orphan Nuclear Receptors; 0 / Receptors, Cytoplasmic and Nuclear; 0 / liver X receptor; 17711-16-9 / 22-hydroxycholesterol; 3XMK78S47O / Testosterone; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.2 / alcohol sulfotransferase
  • [Other-IDs] NLM/ PMC2488233
  •  go-up   go-down


2. Jordan E, Choe D, Miller T, Chamarthy M, Brook A, Freeman LM: Utility of bone scintigraphy to determine the appropriate vertebral augmentation levels. Clin Nucl Med; 2010 Sep;35(9):687-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF THE REPORT: Vertebral augmentation procedures have been used as an effective treatment for back pain due to vertebral compression fracture from different causes, including metastatic disease and osteoporosis.
  • The data was reviewed by a panel consisting of a neuroradiologist and nuclear medicine physician for agreement.
  • RESULTS AND CONCLUSIONS: Our retrospective study assessed the utility of bone scans as a diagnostic tool to identify candidate vertebral levels for vertebroplasty and determined that bone scans were positive in 78.3% of all fractures that subsequently underwent vertebral augmentation procedures.
  • Although no significant difference was seen in the positivity of bone scans to subsequent vertebroplasty levels between benign or metastatic compression fractures (79% vs. 76%), a difference was observed when single level vertebroplasty patients were compared with multiple-level vertebroplasty patients (87% vs. 69%).
  • Our results support the use of whole body bone scintigraphy as a diagnostic tool prior to vertebroplasty, especially in cases where a single vertebral level is involved or MRI might be contraindicated.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Neoplasm Metastasis. Osteoporosis / radionuclide imaging. Osteoporosis / surgery. Spinal Fractures / radionuclide imaging. Spinal Fractures / surgery. Spinal Neoplasms / radionuclide imaging. Spinal Neoplasms / surgery. Whole-Body Irradiation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706042.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Kim TJ, Moon WK, Cha JH, Goo JM, Lee KH, Kim KH, Lee JW, Han JG, Weinmann HJ, Chang KH: VX2 carcinoma in rabbits after radiofrequency ablation: comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor. Radiology; 2005 Feb;234(2):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VX2 carcinoma in rabbits after radiofrequency ablation: comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor.
  • PURPOSE: To prospectively compare the accuracy of a blood pool agent, SH L 643A, with that of gadopentetate dimeglumine in differentiating benign periablational enhancement from residual tumor in VX2 carcinomas in rabbits after radiofrequency (RF) ablation.
  • Sequential MR images were obtained before and with SH L 643A (17 000 Da, 0.05 mmol/kg) and, after a 24-hour interval, gadopentetate dimeglumine (546 Da, 0.1 mmol/kg) in 12 rabbits with VX2 carcinoma in the back muscle prior to (n = 12) and early (n = 12), 1 week (n = 8), and 4 weeks (n = 4) after RF ablation.
  • The pathologic specimens were sectioned in the same plane as MR imaging, and the enhancement ratios (ie, the ratios of postcontrast to precontrast signal intensity) and the microvessel densities of residual tumor and benign periablational enhancement were assessed.
  • RESULTS: With SH L 643A, the peak enhancement ratios of residual tumor (1.64 +/- 0.31 [standard deviation]) were significantly higher than those of benign periablational enhancement (0.97 +/- 0.16) (P < .001).
  • With gadopentetate dimeglumine, the peak enhancement ratios of residual tumor (1.82 +/- 0.33) were not different from those of benign periablational enhancement (1.71 +/- 0.36).
  • In benign periablational enhancement, enhancement ratios with injection of SH L 643A were lower than those with injection of gadopentetate dimeglumine for all time points up to 30 minutes (P < .05).
  • The microvessel density was 25.72 +/- 5.43 vessels per field of view for residual tumor and 10.37 +/- 2.88 vessels per field of view for benign periablational enhancement (P < .001).
  • CONCLUSION: Blood pool contrast agent SH L 643A permits more accurate differentiation of benign periablational enhancement from residual tumor compared with the extracellular agent gadopentetate dimeglumine.
  • [MeSH-major] Catheter Ablation. Contrast Media. Gadolinium. Gadolinium DTPA. Magnetic Resonance Imaging. Neoplasm, Residual / diagnosis. Neoplasms, Experimental / surgery
  • [MeSH-minor] Animals. Diagnosis, Differential. Prospective Studies. Rabbits

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2004.
  • [CommentIn] Radiology. 2005 Feb;234(2):317-8 [15670988.001]
  • [CommentIn] Radiology. 2005 Nov;237(2):745-7; author reply 748-9 [16244283.001]
  • [ErratumIn] Radiology. 2005 Nov;237(2):750
  • (PMID = 15591437.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / gadomer 17; AU0V1LM3JT / Gadolinium; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


Advertisement
4. Mitra R: Osteitis Condensans Ilii. Rheumatol Int; 2010 Jan;30(3):293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteitis Condensans Ilii (OCI) is a benign cause of axial low back pain.
  • Clinicians must be guided by history, radiographic findings, and laboratory studies in differentiating OCI with other disorders; furthermore additional causes of low back pain including metastatic disease and ankylosing spondylitis must be ruled out.
  • Treatments for the condition are primarily conservative (therapies, non-steroidal anti-inflammatory medications, and steroid injections), with surgical resection being reserved for refractory cases.
  • [MeSH-major] Ilium / pathology. Ilium / physiopathology. Low Back Pain / etiology. Low Back Pain / physiopathology. Osteitis / diagnosis. Osteitis / physiopathology
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Diagnosis, Differential. Humans. Neoplasm Metastasis / diagnosis. Radiography. Radiology. Sacroiliac Joint / diagnostic imaging. Sacroiliac Joint / pathology. Sacroiliac Joint / physiopathology. Spondylitis, Ankylosing / diagnosis. Steroids / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chir Organi Mov. 1989 Jul-Dec;74(3-4):101-7 [2635651.001]
  • [Cites] Lancet. 1975 May 17;1(7916):1135-6 [49487.001]
  • [Cites] Lancet. 1975 Apr 5;1(7910):812 [48046.001]
  • [Cites] J Bone Joint Surg Am. 1950 Oct;32 A(4):841-7 [14784494.001]
  • [Cites] Br J Rheumatol. 1996 Mar;35(3):295-7 [8620310.001]
  • [Cites] Aten Primaria. 1993 Mar 31;11(5):239-41 [8471706.001]
  • [Cites] J Rheumatol Suppl. 1977;3:105-8 [266591.001]
  • [Cites] J Rheumatol. 1988 Jun;15(6):1035-7 [3418630.001]
  • [Cites] Postgrad Med J. 2005 Jan;81(951):65-7 [15640434.001]
  • [Cites] Clin Nucl Med. 2004 May;29(5):320-1 [15069334.001]
  • [Cites] AJR Am J Roentgenol. 1978 Jun;130(6):1125-31 [418651.001]
  • [Cites] JBR-BTR. 2007 Sep-Oct;90(5):350-7 [18085189.001]
  • [Cites] Radiology. 1971 Jan;98(1):1-8 [4250709.001]
  • [Cites] Lancet. 1974 Aug 31;2(7879):522-3 [4136917.001]
  • [Cites] Br J Radiol. 1953 Jan;26(301):16-21 [13019060.001]
  • [Cites] J Rheumatol. 1990 Nov;17 (11):1504-12 [2273492.001]
  • [Cites] Scand J Rheumatol. 1985;14 (2):163-6 [3873700.001]
  • [Cites] J Rheumatol. 1990 Nov;17 (11):1515-9 [2273494.001]
  • [Cites] Br J Rheumatol. 1994 Jun;33(6):599-600 [8205417.001]
  • [Cites] Semin Musculoskelet Radiol. 2008 Mar;12(1):72-82 [18382946.001]
  • (PMID = 19711079.001).
  • [ISSN] 1437-160X
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Steroids
  • [Number-of-references] 24
  •  go-up   go-down


5. Wadhwa RK, Shaya MR, Nanda A: Spinal cord compression in a patient with a pain pump for failed back syndrome: a chalk-like precipitate mimicking a spinal cord neoplasm: case report. Neurosurgery; 2006 Feb;58(2):E387; discussion E387
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression in a patient with a pain pump for failed back syndrome: a chalk-like precipitate mimicking a spinal cord neoplasm: case report.
  • OBJECTIVE AND IMPORTANCE: The use of intrathecal morphine has been effective with few complications for chronic intractable pain of both benign and malignant origins.
  • A rare but serious problem that exists is the formation of an inflammatory mass at the catheter tip of the pain pump.
  • CLINICAL PRESENTATION: We report the case of a 67-year-old female patient with failed back syndrome who presented with sensory complaints and back pain.
  • [MeSH-minor] Aged. Back Pain / drug therapy. Back Pain / radiography. Bupivacaine / administration & dosage. Diagnosis, Differential. Female. Humans. Syndrome

  • Genetic Alliance. consumer health - Spinal cord neoplasm.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM CARBONATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462469.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] H0G9379FGK / Calcium Carbonate; Y8335394RO / Bupivacaine
  •  go-up   go-down






Advertisement